Dashboard
Manage Tickers

JNJJOHNSON & JOHNSON

NYSE jnj.com


$ 149.33 $ -0.65 (-0.43 %)    

Friday, 03-May-2024 15:59:56 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 435.98 $ 8.58 (2.01 %)
DIA $ 386.87 $ 4.54 (1.19 %)
SPY $ 511.25 $ 6.26 (1.24 %)
TLT $ 89.88 $ 0.90 (1.01 %)
GLD $ 212.97 $ -0.17 (-0.08 %)
$ 149.27
$ 150.23
$ 0.00 x 0
$ 0.00 x 0
$ 147.82 - $ 150.23
$ 142.71 - $ 172.01
6,532,718
na
362.74B
$ 0.49
$ 9.43
TBD
na
na ($ 0.03)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-01-2024 03-31-2024 10-Q
2 02-16-2024 12-31-2023 10-K
3 10-27-2023 10-01-2023 10-Q
4 10-27-2023 10-01-2023 10-Q
5 07-31-2023 07-02-2023 10-Q
6 04-28-2023 04-02-2023 10-Q
7 02-16-2023 01-01-2023 10-K
8 10-27-2022 10-02-2022 10-Q
9 07-29-2022 07-03-2022 10-Q
10 04-29-2022 04-03-2022 10-Q
11 02-17-2022 01-02-2022 10-K
12 10-29-2021 10-03-2021 10-Q
13 07-29-2021 07-04-2021 10-Q
14 04-30-2021 04-04-2021 10-Q
15 02-22-2021 01-03-2021 10-K
16 10-23-2020 09-27-2020 10-Q
17 07-24-2020 06-28-2020 10-Q
18 04-29-2020 03-29-2020 10-Q
19 02-18-2020 12-29-2019 10-K
20 10-28-2019 09-29-2019 10-Q
21 07-29-2019 06-30-2019 10-Q
22 05-01-2019 03-31-2019 10-Q
23 02-20-2019 12-30-2018 10-K
24 10-31-2018 09-30-2018 10-Q
25 08-02-2018 07-01-2018 10-Q
26 05-01-2018 04-01-2018 10-Q
27 02-21-2018 12-31-2017 10-K
28 11-02-2017 10-01-2017 10-Q
29 08-03-2017 07-02-2017 10-Q
30 05-08-2017 04-02-2017 10-Q
31 02-27-2017 01-01-2017 10-K
32 11-04-2016 10-02-2016 10-Q
33 08-04-2016 07-03-2016 10-Q
34 05-10-2016 04-03-2016 10-Q
35 02-24-2016 01-03-2016 10-K
36 10-30-2015 09-27-2015 10-Q
37 07-31-2015 06-28-2015 10-Q
38 05-01-2015 03-29-2015 10-Q
39 02-24-2015 12-28-2014 10-K
40 10-30-2014 09-28-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

johnson--johnson-announces-phase-2-data-for-erleada-plus-androgen-deprivation-therapy-following-radical-prostatectomy-in-patients-with-high-risk-localized-prostate-cancer-show-100-biochemical-free-recurrence-rate-more-than-two-years-post-surgery-study-met-its-primary-endpoint-safety-profile-of-erleada-with-adt-was-consistent-with-previous-reports
Johnson & Johnson Announces Phase 2 Data F...
05/03/2024 16:23:19

Study highlights opportunity for treatment intensification in this population since approximately 50% of patients with high-ris...

johnson--johnson-says-tar-200-monotherapy-shows-greater-than-80-complete-response-rate-in-patients-with-high-risk-non-muscle-invasive-bladder-cancer-new-data-from-phase-2b-sunrise-1-study-show-rapid-achievement-of-complete-response-with-98-achieving-a-cr-within-12-weeks
Johnson & Johnson Says TAR-200 Monotherapy...
05/03/2024 15:20:51

- Reuters

nasdaq-sp-500-futures-rise-ahead-of-apple-earnings-why-this-analyst-thinks-no-cut-scenario-may-not-be-negative-for-market
Nasdaq, S&P 500 Futures Rise Ahead Of Appl...
05/02/2024 10:52:51

U.S. stocks look to push ahead on a positive path, now that the Federal Reserve’s rate decision is in the rearview mirror. Majo...

johnson--johnson-wants-to-deal-with-talc-lawsuit-overhang-proposes-65b-settlement-package
Johnson & Johnson Wants To Deal With Talc ...
05/01/2024 18:42:19

Johnson & Johnson announces $6.475 billion settlement for talc-related ovarian cancer lawsuits. Details on proposed resolut...

johnson--johnson-disclosed-a-proposed-plan-of-reorganization-for-the-comprehensive-and-final-resolution-of-all-current-and-future-claims-related-to-ovarian-cancer-arising-from-cosmetic-talc-litigation-against-it-and-its-affiliates-in-us
Johnson & Johnson Disclosed A Proposed Pla...
05/01/2024 10:39:04

spotlight-on-johnson--johnson-analyzing-the-surge-in-options-activity
Spotlight on Johnson & Johnson: Analyzing ...
04/30/2024 18:46:29

johnson--johnson-partnered-addex-therapeutics-epilepsy-candidate-fails-mid-stage-study-stock-tanks
Johnson & Johnson-Partnered Addex Therapeu...
04/29/2024 14:53:51

Latest Phase 2 epilepsy study findings on ADX71149 adjunctive therapy for focal onset seizures. Partnered with Janssen, Addex T...

jj-says-chmp-recommends-conversion-of-conditional-marketing-authorization-for-sirturo-bedaquiline-into-standard-marketing-authorization
J&J Says CHMP Recommends Conversion Of Con...
04/29/2024 14:19:45

- Reuters

johnson--johnson-receives-positive-chmp-opinion-recommending-full-approval-for-sirturo-for-treatment-of-multidrug-resistant-tuberculosis
Johnson & Johnson Receives Positive CHMP O...
04/29/2024 14:17:48

- Reuters

Core News & Articles
Cidara Therapeutics Reacquires Global Deve...
04/24/2024 20:47:52

- $240 million private placement financing led by RA Capital Management with significant participation by Bain Capital Life Sci...

johnson--johnson-childrens-cough-syrup-contaminated-in-some-batches---who-poised-to-issue-global-alert-updated
Johnson & Johnson Children's Cough Syrup C...
04/23/2024 20:21:54

WHO alerts the global community about tainted children's cough syrup by Johnson & Johnson. Elevated toxin levels detect...

ec-approved-carvykti-for-treatment-of-relapsedrefractory-multiple-myeloma
EC Approved Carvykti For Treatment Of Rela...
04/22/2024 11:57:29

-Bloomberg

brexit-impact-on-drugs---rising-shortages-in-uk-highlight-brexit-challenges
Brexit Impact On Drugs - Rising Shortages ...
04/19/2024 15:39:26

Discover the impact of Brexit on UK drug shortages. Insights from a recent Nuffield Trust study reveal a doubling in shortages ...

fda-mandates-boxed-warning-for-bristol-myers-johnson--johnson-car-t-based-blood-cancer-therapies
FDA Mandates "Boxed Warning" For Bristol M...
04/19/2024 13:28:52

Following an investigation announced in November last year, the FDA said on Thursday that it would now require boxed warnings—t...

hsbc-upgrades-johnson--johnson-to-buy-raises-price-target-to-170
HSBC Upgrades Johnson & Johnson to Buy, Ra...
04/18/2024 15:41:33

HSBC analyst Morten Herholdt upgrades Johnson & Johnson (NYSE:JNJ) from Hold to Buy and raises the price target from $16...

unpacking-the-latest-options-trading-trends-in-johnson--johnson
Unpacking the Latest Options Trading Trend...
04/18/2024 14:32:29

johnson--johnson-shares-hold-steady-after-q1-earnings-analysts-optimistic-about-future
Johnson & Johnson Shares Hold Steady After...
04/17/2024 19:37:34

Johnson & Johnson reports first-quarter earnings, with adjusted EPS up 12.4% and sales up 2.3%. Analysts optimistic about s...

johnson--johnson-analysts-cut-their-forecasts-after-q1-results
Johnson & Johnson Analysts Cut Their Forec...
04/17/2024 17:51:23

Johnson & Johnson (NYSE: JNJ) reported better-than-expected first-quarter earnings on Tuesday.

rbc-capital-maintains-outperform-on-johnson--johnson-lowers-price-target-to-175
RBC Capital Maintains Outperform on Johnso...
04/17/2024 17:11:42

RBC Capital analyst Shagun Singh maintains Johnson & Johnson (NYSE:JNJ) with a Outperform and lowers the price target fr...

cantor-fitzgerald-reiterates-overweight-on-johnson--johnson-maintains-215-price-target
Cantor Fitzgerald Reiterates Overweight on...
04/17/2024 13:28:36

Cantor Fitzgerald analyst Louise Chen reiterates Johnson & Johnson (NYSE:JNJ) with a Overweight and maintains $215 price...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION